Helping Your Patients Afford Ebglyss

You've determined that Ebglyss (lebrikizumab-lbkz) is the right treatment for your patient's moderate-to-severe atopic dermatitis. Now comes the part that often derails treatment plans: cost. As a specialty biologic with no generic alternative, Ebglyss carries a significant price tag — and your patients are likely going to need help navigating their options.

This guide covers the financial assistance landscape for Ebglyss and how you can proactively support your patients through it.

What Patients Are Paying

The wholesale acquisition cost of Ebglyss runs approximately $2,500 to $3,800 per injection, translating to roughly $3,200 per month during maintenance dosing. For patients without robust insurance coverage, this is a non-starter.

Even with commercial insurance, out-of-pocket costs vary widely depending on the plan's specialty tier copay, coinsurance structure, and annual out-of-pocket maximum. Many patients face:

• Specialty tier copays of $100–$500+ per fill
• Coinsurance of 20–30% until deductible is met
• Prior authorization requirements (nearly universal)
• Step therapy mandates — often requiring documentation of inadequate response to topical corticosteroids and possibly Dupixent

Medicare Part D beneficiaries face additional complexity, as manufacturer copay cards generally cannot be applied to government-funded insurance programs.

Manufacturer Savings Programs

Eli Lilly Ebglyss Savings Card

The primary cost-reduction tool for commercially insured patients. Key details:

• Eligible patients may pay as little as $0 per injection
• Maximum annual benefit applies (check current terms at ebglyss.com)
• Available to patients with commercial insurance — not available for Medicare, Medicaid, or other government insurance
• Enrollment: ebglyss.com or 1-800-545-6962

Provider tip: Have your staff proactively enroll patients during the prior authorization process. Don't wait for the patient to encounter sticker shock at the pharmacy.

Lilly Cares Foundation Patient Assistance Program

For uninsured or underinsured patients who meet income eligibility criteria:

• Provides Ebglyss at no cost
• Application at lillycares.com or via 1-800-545-6962
• Requires documentation of financial need

This program is especially important for patients who fall through coverage gaps — those who don't qualify for Medicaid but can't afford commercial premiums or high deductibles.

Coupon and Discount Resources

Beyond manufacturer programs, several third-party resources may help patients identify additional savings:

• MedFinder for Providers: medfinder.com/providers helps your practice stay informed about specialty pharmacy availability and patient cost resources.
• Specialty pharmacy financial counseling: Most specialty pharmacies (Accredo, CVS Specialty, OptumRx Specialty) have dedicated financial assistance teams that can help identify coverage options.
• Foundation grants: Organizations like the Patient Access Network (PAN) Foundation, HealthWell Foundation, and National Eczema Association sometimes offer copay assistance grants for dermatologic biologics. Availability varies by funding cycle.

For a patient-facing version of cost-saving strategies, direct patients to our guide to saving money on Ebglyss.

Generic and Biosimilar Alternatives

There is currently no generic or biosimilar version of Ebglyss available. As a biologic under patent protection, biosimilar competition is not expected in the near term.

If cost is prohibitive despite assistance programs, therapeutic alternatives to consider include:

• Dupixent (dupilumab) — IL-4/IL-13 dual inhibitor; has been on the market longer and may have broader insurance coverage and more established savings programs
• Adbry (tralokinumab) — Another IL-13 inhibitor with a similar mechanism
• Rinvoq (upadacitinib) or Cibinqo (abrocitinib) — Oral JAK inhibitors; different risk profile but may be preferred by patients who want to avoid injections

For more on switching between therapies, see our alternatives to Ebglyss guide. For supply and availability considerations, our provider shortage update has the latest.

Having Cost Conversations with Patients

Cost is one of the top reasons patients don't fill specialty prescriptions. Proactive, transparent conversations make a difference:

• Bring it up first. Don't wait for patients to ask. Many won't — they'll just not fill the prescription.
• Frame it with solutions. Instead of "this medication is expensive," try: "This medication has a high list price, but most of my patients end up paying very little out of pocket. Let's make sure you're enrolled in the savings program before we send the prescription."
• Assign a team member. If possible, designate someone in your office (nurse, MA, or PA coordinator) as the point person for specialty pharmacy and financial assistance navigation.
• Follow up. Check in at the first follow-up visit to confirm the patient actually received and started the medication. Delays in specialty pharmacy fulfillment are common.

Streamlining Your Workflow

A few operational tips to reduce friction:

• Start prior authorization early. Initiate PA at the same visit you decide to prescribe. Insurance turnaround times vary from days to weeks.
• Document step therapy thoroughly. Include specific dates, durations, and outcomes of prior treatments in your PA submission. Vague documentation is the #1 reason for denials.
• Use electronic PA tools. Many EHR systems integrate with CoverMyMeds or similar platforms that expedite the process.
• Build relationships with specialty pharmacies. Having a direct contact at 1-2 specialty pharmacies speeds up communication and issue resolution.

Final Thoughts

The clinical value of Ebglyss for appropriate patients is clear. The challenge is making sure cost doesn't become a barrier. By proactively enrolling patients in savings programs, communicating transparently about cost, and building efficient workflows around prior authorization and specialty pharmacy coordination, you can help ensure your patients actually start — and stay on — the treatment you prescribed.

For provider resources and pharmacy availability tools, visit medfinder.com/providers.